Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,355,486
  • Shares Outstanding, K 66,223
  • Annual Sales, $ 44,670 K
  • Annual Income, $ -789,610 K
  • 60-Month Beta 2.32
  • Price/Sales 94.10
  • Price/Cash Flow N/A
  • Price/Book 2.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -3.17
  • Number of Estimates 11
  • High Estimate -0.98
  • Low Estimate -4.36
  • Prior Year -3.73
  • Growth Rate Est. (year over year) +15.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.37 +5.26%
on 07/14/20
68.39 -8.63%
on 08/06/20
-1.50 (-2.34%)
since 07/10/20
3-Month
52.63 +18.73%
on 05/14/20
72.50 -13.81%
on 06/05/20
+2.26 (+3.75%)
since 05/11/20
52-Week
38.95 +60.44%
on 03/17/20
124.15 -49.67%
on 08/20/19
-62.74 (-50.10%)
since 08/09/19

Most Recent Stories

More News
bluebird bio Appoints Denice Torres to Board of Directors

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors.

BLUE : 62.49 (-4.99%)
4 Stocks Downgraded to STRONG SELL

RL, TPR, BLUE, and NOG were recently downgraded to Strong Sell ratings. It's not a good sign when stocks are struggling in a bear market and can indicate serious problems in their businesses. Find out...

RL : 70.21 (+2.23%)
TPR : 15.53 (+0.65%)
BLUE : 62.49 (-4.99%)
NOG : 0.8150 (-1.12%)
After Yesterday's Rally of 5.20% Shares Could Potentially Pullback

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $62.88 to a high of $68.39. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high...

BLUE : 62.49 (-4.99%)
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates

Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BLUE : 62.49 (-4.99%)
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress

--- Elivaldogene autotemcel (eli-cel, Lenti-D gene therapy) in cerebral adrenoleukodystrophy (CALD) granted accelerated assessment of Marketing Authorization Application (MAA) from EMA -

BLUE : 62.49 (-4.99%)
BMY : 63.13 (+2.12%)
BioNTech (BNTX) to Report Q2 Earnings: What's in Store?

During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.

PFE : 37.79 (-1.56%)
BLUE : 62.49 (-4.99%)
ICPT : 52.58 (-0.47%)
BNTX : 68.45 (-7.44%)
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

BMY : 63.13 (+2.12%)
ARCT : 49.25 (-16.40%)
BLUE : 62.49 (-4.99%)
MEIP : 2.79 (+2.57%)
Why Earnings Season Could Be Great for bluebird bio (BLUE)

bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BLUE : 62.49 (-4.99%)
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

AMRN : 6.59 (-5.72%)
ACAD : 40.23 (-2.57%)
BLUE : 62.49 (-4.99%)
ZOM : 0.1520 (-3.43%)
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

AMRN : 6.59 (-5.72%)
ACAD : 40.23 (-2.57%)
BLUE : 62.49 (-4.99%)
AYTU : 1.3100 (-4.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade BLUE with:

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 67.37
1st Resistance Point 64.93
Last Price 62.49
1st Support Level 61.18
2nd Support Level 59.87

See More

52-Week High 124.15
Fibonacci 61.8% 91.61
Fibonacci 50% 81.55
Fibonacci 38.2% 71.50
Last Price 62.49
52-Week Low 38.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar